


# pH-Dependent Cellular Uptake of CPPs – Guanidinium versus Oxyguanidinium Proline

Rahel Heeb, Laura Massaad, Helma Wennemers\*  
Laboratory of Organic Chemistry, ETH Zurich


## Introduction

The delivery of bioactive molecules across cellular membranes represents a significant obstacle to developing protein and nucleic acid-based therapies. Cell penetrating peptides (CPPs) are attractive tools to transport such cargo across the cellular membrane.<sup>1</sup> Our group showed that rigid cationic oligo guanidinium proline (Gup<sub>8</sub>) peptides exhibit higher cellular uptake in comparison to previously established flexible peptides (e.g., octa arginine).<sup>2</sup> Key to their high cellular uptake is their rigidity and charge arrangement in distances of ~9 Å along the PII helical backbone, which enables tight ionic interactions between the cationic guanidinium prolines and anionic cell surface glycans. Building on this work, we developed a CPP analogue in which the guanidinium prolines were replaced with oxyguanidinium prolines (Gop).<sup>3</sup> We studied the conformational properties of Gop derivatives and the cellular uptake in normal versus acidic cancer cell microenvironments.<sup>4</sup>

## Guanidinium versus Oxyguanidinium Proline




## Structural Analysis of Octamers



## Cellular Uptake Studies


### Flow Cytometry



**Ac-(Gup)<sub>8</sub>-NH<sub>2</sub>:**  
 lower uptake upon lowering the pH – cell surface charge change or inhibition of uptake mechanism

**Ac-(Gop)<sub>8</sub>-NH<sub>2</sub>:**  
 higher uptake upon lowering the pH – protonation state of the peptide

### Confocal Microscopy



## Conclusion and Outlook

- Oxyguanidinium proline was introduced as an analogue of guanidinium proline
- The pKa of Gop is 6.8, making it more than 10<sup>5</sup>-fold more acidic than Gup
- The pucker of Gop depends on the pH
- The conformation of the Gop<sub>8</sub> depends on the pH, temperature and solvent
- Our findings render Gop-peptides promising as a tumour tissue specific delivery system

## References

- P.A. Wender et al.; *Adv. Drug Deliv. Rev.* **2008**, *60*, 452–472
- Nagel, Y. A.; Raschle, P. S.; Wennemers, H.; *Angew. Chem. Int. Ed.* **2017**, *56*, 122–126
- For a study with canavanine, see: Calabretta, L. O.; Thomas, V.M.; Raines R.T.; *Tetrahedron Lett.*, **2022**, *99*, 153848
- Riemann, A.; Reime, S.; Thews, O.; *Neoplasia*, **2017**, *19*, 1033–1042

Follow us:

